GlassScriptPhysician profile
Guy R Winzenried
NPI 1578500310
$4,789.11
in general payments reported to CMS, 2019-2025
25 companies · $909 in 2025
The $909 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $159 · 2021: $713 · 2022: $739 · 2023: $606 · 2024: $578 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,093.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.76 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Janssen Biotech, INC. | $563.43 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Boston Scientific Corporation | $474.29 | 2019-2025 | Axonics, Sensation Short Throw, Cre Pro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.06 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $309.00 | 2019-2025 | Entyvio |
| Mauna Kea Technologies, INC. | $287.01 | 2022-2025 | |
| Redhill Biopharma INC. | $222.95 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $141.28 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $129.50 | 2019-2023 | Rebyota |
| Janssen Scientific Affairs, LLC | $124.98 | 2019 | |
| Intercept Pharmaceuticals, INC. | $121.61 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $99.10 | 2024-2025 | Voquezna |
| Celgene Corporation | $98.14 | 2022 | |
| Medtronic USA, INC. | $93.20 | 2019 | |
| Aimmune Therapeutics, INC. | $84.90 | 2024-2025 | Zenpep |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $84.60 | 2022-2025 | Qsymia, Pancreaze |
| Pfizer INC. | $74.52 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $54.32 | 2025 | Dupixent |
| Gilead Sciences, INC. | $51.65 | 2020-2023 | |
| Nestle Healthcare Nutrition INC. | $46.31 | 2021-2022 | |
| Allergan, INC. | $38.10 | 2019-2020 | |
| Braintree Laboratories, INC. | $36.76 | 2019-2021 | |
| Madrigal Pharmaceuticals | $33.47 | 2025 | Rezdiffra |
| Shire North American Group INC | $30.34 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Winzenried listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.